Our results showed that low HER2 expression accounted for 38.2% of the HER2-negative population, which was similar to that of previous studies reporting that approximately 40–50% of breast carcinoma patients express HER2 lowly (8, 9, 15, 16). This evidence concerns the gene ERBB2 and breast carcinoma.